Principal Investigator
Marco Pappagallo, MD
Icahn School of Medicine at Mount Sinai
- 5 trials
- 1 compound
Therapeutic focus
- Major Depressive Disorder
- Chronic Nociceptive Pain
- Neuropathic Pain
- Non-cancer Pain
- Pain
All trials (5)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05081167 | Phase 3 | Completed | Esmethadone (REL-1017) | Relmada Therapeutics, Inc. |
| NCT04855760 | Phase 3 | Completed | Esmethadone (REL-1017) | Relmada Therapeutics, Inc. |
| NCT04688164 | Phase 3 | Completed | Esmethadone (REL-1017) | Relmada Therapeutics, Inc. |
| NCT00945919 | Unknown | Unknown | — | Icahn School of Medicine at Mount Sinai |
| NCT00580294 | Unknown | Completed | — | Icahn School of Medicine at Mount Sinai |
Compounds studied
Trial sites (14)
- Boston, Massachusetts, United States
- Chicago, Illinois, United States
- O'Fallon, Missouri, United States
- Maitland, Florida, United States
- New York, New York, United States
- Orlando, Florida, United States
- Austin, Texas, United States
- Cincinnati, Ohio, United States
- Miami, Florida, United States
- Decatur, Georgia, United States
- Miami Springs, Florida, United States
- Staten Island, New York, United States
- Watertown, Massachusetts, United States
- Palm Bay, Florida, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).